One tri­al down, one to go as Con­cert Phar­ma­ceu­ti­cals tunes up PhI­II win for alope­cia drug

Just two months ago, Con­cert Phar­ma­ceu­ti­cals of­floaded most of its CNS pipeline to tiny Ter­ran Bio­sciences as a make-or-break da­ta read­out was well on its way.

Now, with to­day’s read­out from Con­cert, it looks like the biotech’s sole can­di­date pulled it off — and that the biotech could very well be be­fore the FDA next year.

The Lex­ing­ton, MA biotech an­nounced topline da­ta Mon­day morn­ing that in­di­cat­ed the pri­ma­ry end­point, plus all “key sec­ondary end­points,” were met. The topline da­ta came from THRIVE-AA1, a Phase III tri­al with more than 700 par­tic­i­pants en­rolled and one of Con­cert’s two Phase III tri­als in­ves­ti­gat­ing drug can­di­date CTP-543.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER